Journal
FUTURE CARDIOLOGY
Volume 16, Issue 6, Pages 585-596Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fca-2020-0039
Keywords
anti-arrhythmic drugs; atrial fibrillation; cardioversion; rhythm control; vernakalant
Categories
Funding
- AKCEA
- Amgen
- AMRYT
- LinkMedical
- Napp
- Sanofi
Ask authors/readers for more resources
Vernakalant is an intravenous anti-arrhythmic drug available in Europe, Canada and some countries in Asia for the restoration of sinus rhythm in acute onset atrial fibrillation. Currently, it is not available in USA because the US FDA have ongoing concerns about its safety. Vernakalant has a unique pharmacological profile of multi-ion channel activity and atrial-specificity that distinguishes it from other anti-arrhythmic drugs. This is thought to enhance efficacy but there are concerns of adverse events stemming from its diverse pharmacology. This ambiguity has prompted a review of the available clinical evidence on efficacy and safety to help re-evaluate its place in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available